Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating UTTR1147A versus placebo and vedolizumab in moderate-to-severe ulcerative colitis completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• UTTR1147A (null)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2023-04-14